Yamashita Hideomi, Nakagawa Keiichi, Tago Masao, Nakamura Naoki, Shiraishi Kenshiro, Mafune Ken-Ichi, Kaminishi Michio, Ohtomo Kuni
Department of Radiology, University of Tokyo Hospital, Tokyo, Japan.
Hepatogastroenterology. 2006 Nov-Dec;53(72):863-8.
BACKGROUND/AIMS: To evaluate outcome of the U.S. RTOG/Intergroup Protocol 85-01 for 44 Japanese esophageal cancer patients.
Between 1996 and 2004, patients with esophageal cancer received the Intergroup concurrent chemoradiation therapy regimen for the primary treatment (n=44, group A). We compared the data with those of patients receiving radiotherapy (RT) combined with the weekly chemotherapy regimen (n=12, group B) and with those of patients receiving RT combined with the daily low-dose chemotherapy regimen (n=24, group C).
The median survival period was 14.9 months in group A, 5.7 months in group B, and 6.3 months in group C. The survival rates at 1 and 3 years were 56% and 26% in group A, 42% and 21% in group B (p=0.3307), and 27% and 18% in group C (p=0.0462), respectively.
The prognosis of patients who received the Intergroup regimen for esophageal cancer was significantly better than that of patients who received the daily low-dose chemotherapy regimen. The Intergroup regimen is well tolerable for the Japanese patients too.
背景/目的：评估美国放射肿瘤学组（RTOG）/国际协作组85 - 01方案对44例日本食管癌患者的治疗结果。
1996年至2004年间，食管癌患者接受国际协作组同步放化疗方案作为初始治疗（n = 44，A组）。我们将这些数据与接受放疗（RT）联合每周化疗方案的患者（n = 12，B组）以及接受RT联合每日低剂量化疗方案的患者（n = 24，C组）的数据进行比较。
A组的中位生存期为14.9个月，B组为5.7个月，C组为6.3个月。A组1年和3年生存率分别为56%和26%，B组为42%和21%（p = 0.3307），C组为27%和18%（p = 0.0462）。
接受国际协作组食管癌方案治疗的患者预后明显优于接受每日低剂量化疗方案的患者。国际协作组方案对日本患者的耐受性也良好。
